Form 4: Black Diamond Therapeutics Director Shannon Campbell Acquires Shares in Lieu of Cash Compensation

Director Shannon Campbell of Black Diamond Therapeutics acquired 4,500 shares of common stock in lieu of cash compensation and disposed of 8,865 shares.

Summary

• Shannon Campbell, a director at Black Diamond Therapeutics, acquired 4,500 shares of common stock on December 13, 2024.
• These shares were received in lieu of cash compensation for annual services as a non-employee director.
• The price of the shares was $2.5, based on the closing market price on December 12, 2024.
• The director also disposed of 8,865 shares.

Sentiment

Score: 5

Explanation: The document is neutral, reporting a standard transaction. The acquisition of shares is a positive sign, but the disposal of shares is a negative sign. The overall sentiment is therefore neutral.

Positives

• The acquisition of shares by a director demonstrates confidence in the company's future.

Negatives

• The disposal of 8,865 shares by the director could be seen as a negative signal.

Risks

• The disposal of shares by a director could indicate a lack of confidence in the company's future performance.
• The market price of the stock could be volatile.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders buy or sell shares. It provides transparency into the transactions of company directors.

Comparison to Industry Standards

• Form 4 filings are a standard practice for all publicly traded companies in the US.
• The transaction is typical for directors receiving stock compensation in lieu of cash.
• The share price of $2.5 is specific to Black Diamond Therapeutics and would need to be compared to other similar biotech companies to assess its relative value.

Stakeholder Impact

• Shareholders may view the director's share acquisition as a positive sign, but the disposal of shares could raise concerns.

Key Dates

Keywords

Black Diamond Therapeutics, Director, Share Acquisition, Share Disposal, Stock Compensation, Form 4, Insider Trading